Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval
Open Access
- 1 January 2011
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 22 (1), 49-58
- https://doi.org/10.1093/annonc/mdq353
Abstract
Background: OVA-301 is a large randomized trial that showed superiority of trabectedin plus pegylated liposomal doxorubicin (PLD; CentoCor Ortho Biotech Products L.P., Raritan, NJ, USA). over single-agent PLD in 672 patients with relapsed ovarian cancer, particularly in the partially platinum-sensitive subgroup [platinum-free interval (PFI) of 6–12 months]. This superiority has been suggested to be due to the differential impact of subsequent (platinum) therapy.Funding Information
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C., and Pharma Mar
This publication has 25 references indexed in Scilit:
- Trabectedin: an anticancer drug from the seaExpert Opinion on Pharmacotherapy, 2009
- Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different SchedulesJournal of Clinical Oncology, 2009
- Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancerAnnals of Oncology, 2009
- Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO groupBritish Journal of Cancer, 2009
- Mapping the literature: Role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcomaDrugs of Today, 2009
- A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimensBritish Journal of Cancer, 2007
- TrabectedinDrugs, 2007
- Management of Platinum-Sensitive Recurrent Ovarian CancerSeminars in Oncology, 2006
- Extending the Platinum-Free Interval with a Non-Platinum Therapy in Platinum-Sensitive Recurrent Ovarian CancerOncology, 2006
- Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistanceInternational Journal of Gynecologic Cancer, 2005